selected scholarly activity
-
chapters
- The secondary prevention of cardiovascular disease. 769-791. 2005
-
conferences
- The "Hub and Spoke" Model of Heart Function Care Achieves Quality Index Markers. Circulation. 2018
- First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study. Stroke. 2018
- Women with stable coronary artery disease have better clinical outcomes than men, but this association is modified by degree of depression: insights from the STABILITY trial. European Heart Journal. 188-188. 2017
- [PP.26.05] BLOOD PRESSURE LOWERING IN INTERMEDIATE RISK PEOPLE WITHOUT VASCULAR DISEASE. Journal of Hypertension. e274-e275. 2016
- Effects of Insulin Glargine on Left Ventricular Mass and Function in Patients With Dysglycemia. Circulation. 2014
- Effects of School-Based Interventions on Body Mass Index in Children and Adolescents: a Systematic Overview and Meta-analysis. Circulation. 2014
- Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study. Circulation. 2014
- Relationships Between 'Mediterranean' and 'Western' Dietary Patterns and Major Cardiovascular Events in Patients With Stable Coronary Heart Disease in the STABILITY Study. Circulation. 2014
- Relationship of PCSK9 With Measures of Vascular Disease and Global Risk in 1574 Individuals Enrolled in the FATE (Fireman And Their Endothelium) Study. Circulation. 2013
- Echocardiographic Assessment of Tricuspid Valve Regurgitation Induced by Temporary or Permanent Leads in Patients Undergoing Ablation or Permanent Device Implantation. Canadian Journal of Cardiology. S160-S160. 2013
- Low Omega-3 Index in Erythrocytes Is a Risk Factor for Progression of Atherosclerosis in People Living With HIV. Canadian Journal of Cardiology. S168-S168. 2013
- Effects of Dulaglutide, A GLP-1 Agonist, on Ambulatory Diurnal and Nocturnal Blood Pressure in Patients with Type 2 Diabetes. Journal of Clinical Hypertension. 2013
- 247 How Do Canadian Primary Care Physicians in Family Health Teams Compare With Those in Solo-Physician Practices in Their Assessment and Management of Patients With Elevated Cardiometabolic Risk?. Canadian Journal of Cardiology. S182-S183. 2012
- 248 Underestimation of Cardiovascular Risk in Patients With Elevated Cardiometabolic Risk in the Canadian Primary Care Setting. Canadian Journal of Cardiology. S183-S184. 2012
- 750 Are Lifestyle Modifications Being Appropriately Recommended in the Canadian Primary Care Practice to Manage Elevated Cardiometabolic Risk?. Canadian Journal of Cardiology. S387-S387. 2012
- Heart Rate is associated with Increased Risk of Major Cardiovascular Events, Cardiovascular and All-Cause Death in Patients with Stable Chronic Cardiovascular Disease - An Analysis of ONTARGET/TRANSCEND. Circulation. 2010
- HEART RATE IS ASSOCIATED WITH INCREASED RISK OF MAJOR CARDIOVASCULAR EVENTS, CARDIOVASCULAR AND ALL-CAUSE DEATH IN PATIENTS WITH STABLE CHRONIC CARDIOVASCULAR DISEASE - ANALYSIS OF ONTARGET/TRANSCEND. Canadian Journal of Cardiology. 76D-76D. 2010
- PLASMA RENIN ACTIVITY PREDICTS CARDIOVASCULAR EVENTS AND MORTALITY IN THE HEART OUTCOMES PREVENTION EVALUATION (HOPE) STUDY. Canadian Journal of Cardiology. 76D-76D. 2010
- Premature Risk of Stroke in Recent Immigrants (PRESARIO): Population-based Matched Cohort Study. Stroke. E388-E388. 2010
- Plasma Renin Activity is Associated With Increased Cardiovascular Events and Mortality in the HOPE Study. Circulation. S453-S453. 2009
- Prognostic Significance of Markers of Vascular Health: Long-term Results From the Firefighters And Their Endothelium (FATE) Study. Circulation. S463-S463. 2009
- Homocysteine Lowering Therapy And Stroke Risk, Severity And Disability: Results From The HOPE-2 Trial. Stroke. E131-E131. 2009
- Effect of Rosiglitazone on Left Ventricular Systolic and Diastolic Function and on NT-proBNP: Results of the Echocardiographic and Biomarker Substudy of the DREAM Trial. Circulation. S723-S723. 2008
- Impact of ramipril on the development of prolonged QT interval: results of the Heart Outcomes Prevention Evaluation (HOPE) study. European Heart Journal. 604-604. 2008
- Effect of homocysteine lowering B vitamins on carotid atherosclerosis: The homocysteine and atherosclerosis reduction trial (HART). Canadian Journal of Cardiology. 298C-298C. 2007
- Measures of vascular health: Correlation with the presence of cardiovascular risk factors. Canadian Journal of Cardiology. 118C-118C. 2007
- NT-pro BNP and diastolic dysfunction by echocardiography predicts cardiovascular outcomes in patients with heart failure and preserved systolic function. European Heart Journal. 271-271. 2007
- 156 NT-proBNP predicts cardiovascular outcomes in patients with heart failure and preserved ejection fraction. European Journal of Heart Failure, Supplement. 40-40. 2007
- 59 BNP predicts echocardiographic severity of diastolic dysfunction in heart failure. European Journal of Heart Failure, Supplement. 10-10. 2007
- LV structure in Asians and non-Asians with cardiovascular disease: Results from the ontarget cardiac MRI sub-study. Journal of Hypertension. 142-142. 2006
- Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the heart outcomes prevention evaluation (HOPE) Study. Circulation. 871-871. 2006
- Neither ramipril nor vitamin E reduces the incidence of atrial fibrillation. Results of the HOPE study.. Circulation. 745-746. 2006
- Noninvasive measures of subclinical atherosclerosis in children, a systematic overview. Circulation. 823-823. 2006
- The relationship between metabolic syndrome, according to alternative definitions, and endothelial function among healthy, middle-aged men. The firefighters and their endothelium study. European Heart Journal. 935-935. 2006
- Beneficial effects of ramipril on cardiovascular events in high-risk patients >= 70 years: A subgroup analysis of the HOPE study. Journal of Hypertension. S91-S91. 2006
- Neither Ramipril nor Vitamin E reduce the incidence of atrial fibrillation. Results of the HOPE study. Journal of the American College of Cardiology. 8A-9A. 2006
- Mo-P4:279 Prevalence and predictors of subclinical atherosclerosis among asymptomatic low risk individuals in a multiethnic population. Atherosclerosis Plus. 107-107. 2006
- We-W31:5 Homocysteine and folic acid levels and relation to carotid atherosclerosis in high-risk individuals. Atherosclerosis Plus. 308-308. 2006
- Diastolic dysfunction in heart failure with preserved systolic - Function need for objective evidence. Results from the CHARM echocardiographic substudy - CHARMES. Circulation. U469-U469. 2005
- Relationship of telomere length to endothelial function in healthy middle-aged men. Circulation. U420-U421. 2005
- The effects of Ramipril on C-reactive protein and endothelial function in healthy volunteers at low to intermediate risk: A randomized controlled study. Circulation. U54-U54. 2005
- Diastolic dysfunction in heart failure with preserved systolic function - need for objective evidence. Results from the CHARM Echocardiographic Substudy - CHARMES. European Heart Journal. 14-14. 2005
- Left ventricular mass is lower with candesartan compared to placebo in patients with heart failure and preserved systolic function. Results from the CHARM echocardiographic substudy - CHARMES. Journal of Cardiac Failure. S152-S152. 2005
- Intensity of lipid lowering with statins and brachial artery vascular endothellum reactivity after acute coronary syndromes: The BRAVER trial. Journal of the American College of Cardiology. 248A-248A. 2005
- Antiretroviral exposure and carotid intimal medial thickness in a multicentre Canadian HIV cohort. Antiviral Therapy. L68-L69. 2004
- PCV4 FIRST ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA IN THE THIRD YEAR OF TRIAL PARTICIPATION. Value in Health. 686-686. 2004
- Plasma homocysteine, the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and intima media thickness (IMT) among South Asian, Chinese and European Canadians.. American Journal of Epidemiology. S105-S105. 2004
- Interleukin 18 as a predictor of myocardial infarction in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation. 747-747. 2003
- Obesity predicts atherogenic metabolic abnormalities and atherosclerosis. Circulation. 743-743. 2003
- Relationship between CRP and endothelial function in 1097 asymptomatic middle-age men enrolled in the FATE study. Circulation. 281-281. 2003
- Viral pathogen scores and subsequent cardiac events in the HOPE study. Circulation. 751-751. 2003
- Correlation between noninvasive measures of anatomic extent of subclinical atherosclerosis and endothelial function. Circulation. 652-652. 2002
- Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk diabetic patients. Journal of the American College of Cardiology. 291-291. 2002
- Ramipril prevents major cardiovascular events in high-risk women: results of the HOPE trial. Journal of the American College of Cardiology. 290-291. 2002
- Impact of abdominal obesity on the occurrence of diabetes in subjects with ischemic cardiovascular disease. Circulation. 833-833. 2001
- Infections as risk markers for subsequent cardiovascular events in the HOPE trial. Circulation. 805-805. 2001
- Inflammatory markers and risk of subsequent cardiovascular events in the HOPE trial. Circulation. 791-791. 2001
- Neopterin: Novel marker of endothelial dysfunction in humans. Circulation. 152-152. 2001
- Effects of ramipril on left ventricular mass and function in normotensive, high-risk patients with normal ejection fraction. A substudy of HOPE. Journal of the American College of Cardiology. 165A-165A. 2001
- Metabolic and hematological effects of ramipril in the HOPE trial. Circulation. 408-408. 2000
- Differences in cardiovascular disease between ethnic groups are not explained by conventional risk factors or atherosclerosis. The study of health assessment and risk in ethnic groups (SHARE). Journal of the American College of Cardiology. 283A-284A. 2000
- Left ventricular hypertrophy predicts death and development of heart failure in high risk patients without systolic dysfunction. Journal of the American College of Cardiology. 212A-212A. 2000
- Results of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation. 185-185. 1999
- Is there a gender bias in the cardiovascular drug treatment of high-risk women?. Circulation. 143-143. 1997
- Left ventricular hypertrophy is a potent independent risk factor for adverse cardiovascular outcomes. Circulation. 2600-2600. 1997
- Diabetes is an independent risk factor for increased left ventricular mass. Circulation. 2935-2935. 1996
- EFFECTS OF ORAL ANTICOAGULANTS ON MORTALITY, REINFARCTION AND STROKE AFTER MYOCARDIAL-INFARCTION. Circulation. 1632-1632. 1995
- HIGH-FREQUENCY ULTRASOUND VASCULAR IMAGING. FRONTIERS IN CARDIOVASCULAR IMAGING. 261-274. 1993
- EFFECT OF OXYGEN FREE-RADICALS AND SCAVENGERS ON MYOCARDIAL COLLAGEN DURING ISCHEMIA-REPERFUSION. Circulation. 298-298. 1990
-
journal articles
- Dyslipidemia and the Current State of Cardiovascular Disease: Epidemiology, Risk Factors, and Effect of Lipid Lowering. Canadian Journal of Cardiology. 40:S4-S12. 2024
- Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. The Lancet Diabetes and Endocrinology. 12:306-319. 2024
- Characteristics, management, and outcomes in women and men with congestive heart failure in 40 countries at different economic levels: an analysis from the Global Congestive Heart Failure (G-CHF) registry. The Lancet Global Health. 12:e396-e405. 2024
- Triglyceride-glucose index, low-density lipoprotein levels, and cardiovascular outcomes in chronic stable cardiovascular disease: results from the ONTARGET and TRANSCEND trials. European Journal of Preventive Cardiology (EJPC). 31:311-319. 2024
- “Comfort of Sitting at Home While Getting Information I Needed”: Experiences of Cardiac Patients Attending Virtual Cardiac Rehabilitation. CJC OPEN. 6:133-138. 2024
- The Cost-Effectiveness of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in the COMPASS Trial: A US Perspective. American Journal of Cardiovascular Drugs. 24:117-127. 2024
- Intima-media thickness at the near or far wall of the common carotid artery in cardiovascular risk assessment. European Heart Journal Open. 3:oead089. 2023
- The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial. European Heart Journal - Quality of Care and Clinical Outcomes. 9:502-510. 2023
- Global Variations in Heart Failure Etiology, Management, and Outcomes. Journal of the American Medical Association (JAMA). 329:1650-1650. 2023
- Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial . EuroIntervention. 18:e888-e896. 2022
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. 8:786-795. 2022
- Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk. Cardiovascular Diabetology. 21:12. 2022
- Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. The Lancet. 400:832-845. 2022
- Racial and Ethnic Differences in the Association Between Classical Cardiovascular Risk Factors and Common Carotid Intima‐Media Thickness: An Individual Participant Data Meta‐Analysis. Journal of the American Heart Association. 11:e023704. 2022
- 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. Canadian Journal of Cardiology. 38:1153-1167. 2022
- Cardiovascular responses to high‐intensity stair climbing in individuals with coronary artery disease. Physiological Reports. 10:e15308. 2022
- Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovascular Research (CVR). 118:897-903. 2022
- Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. The Lancet. 398:1133-1146. 2021
- The role of icosapent ethyl in cardiovascular risk reduction. Current Opinion in Cardiology. 36:661-671. 2021
- Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal. 42:2995-3007. 2021
- 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults. Canadian Journal of Cardiology. 37:1129-1150. 2021
- Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. Stroke. 52:2494-2501. 2021
- Cardiovascular outcomes in patients at high cardiovascular risk with previous myocardial infarction or stroke. Journal of Hypertension. 39:1602-1610. 2021
- Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk. Journal of Hypertension. 39:766-774. 2021
- Smoking, Obesity, and Disability Benefits or Litigation Are Not Associated with Clinically Important Reductions in Physical Functioning After Intramedullary Nailing of Tibial Shaft Fractures: A Retrospective Cohort Study. Clinical Orthopaedics and Related Research. 479:805-813. 2021
- Brief Vigorous Stair Climbing Effectively Improves Cardiorespiratory Fitness in Patients With Coronary Artery Disease: A Randomized Trial. Frontiers in Sports and Active Living. 3:630912. 2021
- Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. Stroke. 51:2901-2909. 2020
- Visit-to-visit blood pressure variability and renal outcomes: results from ONTARGET and TRANSCEND trials. Journal of Hypertension. 38:2050-2058. 2020
- Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk. Circulation. 142:621-642. 2020
- Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. European Heart Journal. 41:231-238. 2020
- The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. Gerontology. 66:447-459. 2020
- Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology. 157:682-691.e2. 2019
- Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. European Journal of Heart Failure. 21:998-1007. 2019
- Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology. 157:403-412.e5. 2019
- Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. European Heart Journal. 40:2032-2043. 2019
- Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm. CJC OPEN. 1:190-197. 2019
- The cost implication of primary prevention in the HOPE 3 trial. European Heart Journal - Quality of Care and Clinical Outcomes. 5:266-271. 2019
- What do Physicians Need to Know in Order to ‘Prescribe’ Mobile Applications to Patients with Cardiovascular Disease?. Personalized Medicine. 16:263-268. 2019
- Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. European Journal of Preventive Cardiology (EJPC). 26:681-697. 2019
- Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. Canadian Journal of Cardiology. 35:644-652. 2019
- Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke. 14:270-281. 2019
- Effects of blood pressure and lipid lowering on cognition. Neurology. 92:e1435-e1446. 2019
- Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 393:407-415. 2019
- Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion. Journal of the American College of Cardiology. 73:121-130. 2019
- CardioDiabetes: Core Competencies for Cardiovascular Clinicians in a Rapidly Evolving Era of Type 2 Diabetes Management. Canadian Journal of Cardiology. 34:1350-1361. 2018
- Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. European Heart Journal. 39:3105-3114. 2018
- Effects of Lipid‐Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE‐3 Trial. Journal of the American Heart Association. 7:e008918. 2018
- Vitamin D and progression of carotid intima‐media thickness in HIV‐positive Canadians. HIV Medicine. 19:143-151. 2018
- Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. Canadian Journal of Cardiology. 34:38-44. 2018
- Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 391:205-218. 2018
- Stabilizing selection on microsatellite allele length at arginine vasopressin 1a receptor and oxytocin receptor loci. Proceedings of the Royal Society of London. Biological Sciences. 284:20171896-20171896. 2017
- Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine. 377:1319-1330. 2017
- Association of Apolipoproteins B and A-1 With Markers of Vascular Health or Cardiovascular Events. Canadian Journal of Cardiology. 33:1305-1311. 2017
- Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology. 70:1689-1700. 2017
- Sex Differences in Clinical Characteristics, Psychosocial Factors, and Outcomes Among Patients With Stable Coronary Heart Disease: Insights from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial. Journal of the American Heart Association. 6:e006695. 2017
- Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. The Lancet Diabetes and Endocrinology. 5:597-609. 2017
- Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology. 33:1027-1035. 2017
- A Practical Guide to the Use of Glucose-Lowering Agents With Cardiovascular Benefit or Proven Safety. Canadian Journal of Cardiology. 33:940-942. 2017
- Alcohol Consumption and Common Carotid Intima-Media Thickness: The USE-IMT Study. Alcohol and Alcoholism. 52:483-486. 2017
- Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. The Lancet. 389:2226-2237. 2017
- Primary Prevention With Statin Therapy in the Elderly. Circulation. 135:1979-1981. 2017
-
Metformin in adults with type 1 diabetes:
D esign and methods ofREducing withMetfOrmin V ascularA dverseL esions (REMOVAL ):A n international multicentre trial. Diabetes, Obesity and Metabolism. 19:509-516. 2017 - Diabetes for Cardiologists: Practical Issues in Diagnosis and Management. Canadian Journal of Cardiology. 33:366-377. 2017
- Clustering of cardiovascular risk factors and carotid intima-media thickness: The USE-IMT study. PLoS ONE. 12:e0173393-e0173393. 2017
- 2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 32:1263-1282. 2016
- Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to <120/80 mm Hg Target?. Circulation. 134:1311-1313. 2016
- The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure–Lowering Trials. JAMA cardiology. 1:857-857. 2016
- Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. New England Journal of Medicine. 375:1190-1194. 2016
- Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk. ACP journal club. 165:JC8-JC8. 2016
- Dietary patterns and the risk of major adverse cardiovascular events in a global study of high-risk patients with stable coronary heart disease. European Heart Journal. 37:1993-2001. 2016
- Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2009-2020. 2016
- Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2032-2043. 2016
- Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine. 374:2021-2031. 2016
- Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). Diabetes Care. 39:709-716. 2016
- Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology. 32:311-318. 2016
- Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention. Arteriosclerosis, Thrombosis and Vascular Biology. 35:2254-2259. 2015
-
Low resting heart rates are associated with new‐onset atrial fibrillation in patients with vascular disease: results of the
ONTARGET /TRANSCEND studies. Journal of Internal Medicine. 278:303-312. 2015 - The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. Canadian Journal of Cardiology. 31:1189-1194. 2015
- Young Women With Acute Myocardial Infarction and the Posthospital Syndrome. Circulation. 132:149-151. 2015
-
Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the
ONTARGET andTRANSCEND studies. Journal of Internal Medicine. 278:38-49. 2015 - The New Dyslipidemia Guidelines: What Is the Debate?. Canadian Journal of Cardiology. 31:605-612. 2015
- Common Carotid Intima-Media Thickness Relates to Cardiovascular Events in Adults Aged <45 Years. Hypertension. 65:707-713. 2015
- Systolic Blood Pressure Variation and Mean Heart Rate Is Associated With Cognitive Dysfunction in Patients With High Cardiovascular Risk. Hypertension. 65:651-661. 2015
- Race/Ethnic Differences in the Associations of the Framingham Risk Factors with Carotid IMT and Cardiovascular Events. PLoS ONE. 10:e0132321-e0132321. 2015
- Tricuspid Valve Regurgitation Following Temporary or Permanent Endocardial Lead Insertion, and the Impact of Cardiac Resynchronization Therapy. Open Cardiovascular Medicine Journal. 8:113-120. 2014
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus. Hypertension. 64:731-737. 2014
- Gaps in Medical and Device Therapy for Patients with Left Ventricular Systolic Dysfunction: The EchoGap Study. Open Cardiovascular Medicine Journal. 8:94-101. 2014
- Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals. American Journal of Clinical Nutrition. 100:657-666. 2014
- Common Carotid Intima-Media Thickness Measurements Do Not Improve Cardiovascular Risk Prediction in Individuals With Elevated Blood Pressure. Hypertension. 63:1173-1181. 2014
- Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease. New England Journal of Medicine. 370:1702-1711. 2014
- Incremental Value of Left Ventricular Systolic and Diastolic Function to Determine Outcome in Patients with Acute ST‐Segment Elevation Myocardial Infarction: The Echocardiographic Substudy of the OASIS‐6 Trial. Echocardiography. 31:569-578. 2014
- Are the ACC/AHA Guidelines on the Treatment of Blood Cholesterol a Game Changer? A Perspective From the Canadian Cardiovascular Society Dyslipidemia Panel. Canadian Journal of Cardiology. 30:377-380. 2014
- Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. European Journal of Preventive Cardiology (EJPC). 21:272-280. 2014
- The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: Results from the ONTARGET trial. European Journal of Preventive Cardiology (EJPC). 21:299-309. 2014
- Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal. 35:353-364. 2014
- Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND. Clinical Research in Cardiology. 103:149-159. 2014
- A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. Diabetes, Obesity and Metabolism. 15:1093-1100. 2013
- Physical activity in patients with stable coronary heart disease: an international perspective. European Heart Journal. 34:3286-3293. 2013
- Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus. JAMA Internal Medicine. 173:1682-1692. 2013
- Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events. Diabetes Care. 36:2466-2474. 2013
- Identification and Management of Patients at Elevated Cardiometabolic Risk in Canadian Primary Care: How Well Are We Doing?. Canadian Journal of Cardiology. 29:960-968. 2013
- Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative. Diabetologia. 56:1494-1502. 2013
- Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. Atherosclerosis. 229:234-239. 2013
- Pneumococcal Endocarditis Causing Valve Destruction in the Absence of Vegetations on Transesophageal Echocardiography: A Series of 3 Consecutive Cases. Canadian Journal of Cardiology. 29:519.e7-519.e9. 2013
- Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals. The Lancet. 381:1029-1036. 2013
- 2012 Update of the Canadian Cardiovascular Society Guidelines for the Diagnosis and Treatment of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult. Canadian Journal of Cardiology. 29:151-167. 2013
- The Relationship Between Anthropometric Indexes of Adiposity and Vascular Function in the FATE Cohort. Obesity. 21:266-273. 2013
- The relationship between anthropometric indexes of adiposity and vascular function in the FATE cohort. Obesity. 21:266-273. 2013
- Increased cardiovascular risk after pre‐eclampsia in women with dysglycaemia. Diabetic Medicine. 30:e1-e7. 2013
- Multivitamins in Prevention of Cardiovascular Disease. Journal of the American Medical Association (JAMA). 308:1802-1802. 2012
- Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease. CANADIAN MEDICAL ASSOCIATION JOURNAL. 184:E857-E866. 2012
- Common Carotid Intima-Media Thickness Measurements in Cardiovascular Risk Prediction. Journal of the American Medical Association (JAMA). 308:796-796. 2012
- Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. New England Journal of Medicine. 367:319-328. 2012
- n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia. New England Journal of Medicine. 367:309-318. 2012
- Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. European Heart Journal. 33:1049-1057. 2012
- Cardiovascular risk factors and subclinical atherosclerosis among Nunavik Inuit. Atherosclerosis. 221:558-564. 2012
- Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. European Heart Journal. 32:2135-2142. 2011
- The Fluid Study Protocol: A Randomized Controlled Study on the Effects of Bioimpedance Analysis and Vitamin D on Left Ventricular Mass in Peritoneal Dialysis Patients. Advances in peritoneal dialysis. Conference on Peritoneal Dialysis. 31:529-536. 2011
- Cardiometabolic Risk in Canada: A Detailed Analysis and Position Paper by the Cardiometabolic Risk Working Group. Canadian Journal of Cardiology. 27:e1-e33. 2011
- Identification and Management of Cardiometabolic Risk in Canada: A Position Paper by the Cardiometabolic Risk Working Group (Executive Summary). Canadian Journal of Cardiology. 27:124-131. 2011
- Epicardial fat thickness and coronary artery disease correlate independently of obesity. International Journal of Cardiology. 146:452-454. 2011
- Microvascular Function Predicts Cardiovascular Events in Primary Prevention. Circulation. 123:163-169. 2011
- The Polypill in the Prevention of Cardiovascular Diseases. Circulation. 122:2078-2088. 2010
- Relation Between Obesity and the Attainment of Optimal Blood Pressure and Lipid Targets in High Vascular Risk Outpatients. American Journal of Cardiology. 106:1270-1276. 2010
- Effects of Lowering Homocysteine Levels With B Vitamins on Cardiovascular Disease, Cancer, and Cause-Specific Mortality<subtitle>Meta-analysis of 8 Randomized Trials Involving 37 485 Individuals</subtitle><alt-title>Effects of Lowering Homocysteine Levels</alt-title>. JAMA Internal Medicine. 170:1622-1622. 2010
- Corrections. Hypertension. 56:E36-E36. 2010
- Myocardial infarction Associated with Recency of Immigration to Ontario. QJM - Monthly Journal of the Association of Physicians. 103:253-258. 2010
- Lipoprotein-associated phospholipase A2: A new therapeutic target. Canadian Journal of Cardiology. 26:27A-31A. 2010
- Risk of premature stroke in recent immigrants (PRESARIO). Neurology. 74:451-457. 2010
- Cardiovascular risk factors and non-invasive assessment of subclinical atherosclerosis in youth. Atherosclerosis. 208:501-505. 2010
- Left Ventricular Mass and Volume With Telmisartan, Ramipril, or Combination in Patients With Previous Atherosclerotic Events or With Diabetes Mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). American Journal of Cardiology. 104:1484-1489. 2009
- Polypill: the evidence and the promise. Current Opinion in Lipidology. 20:453-459. 2009
- The differential association between various anthropometric indices of obesity and subclinical atherosclerosis. Atherosclerosis. 207:232-238. 2009
- 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Canadian Journal of Cardiology. 25:567-579. 2009
- Lipid lowering for primary prevention (vol 373, pg 1152, 2009). The Lancet. 374:28-28. 2009
- Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: The Ramipril C-Reactive pRotein Randomized evaluation (4R) trial results. Canadian Journal of Cardiology. 25:e236-e240. 2009
- Response to Letter by Obeid and Herrmann. Stroke. 40:E517-E517. 2009
- The Prognostic Significance of Bundle Branch Block in High‐Risk Chronic Stable Vascular Disease Patients: A Report from the HOPE Trial. Journal of Cardiovascular Electrophysiology. 20:781-787. 2009
- The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics. Clinical Research in Cardiology. 98:421-433. 2009
- 5 flourouracil-induced apical ballooning syndrome: a case report. Blood Coagulation and Fibrinolysis. 20:306-308. 2009
- Comparison of New Measures of Vascular Function to Flow Mediated Dilatation as a Measure of Cardiovascular Risk Factors. American Journal of Cardiology. 103:1610-1615. 2009
- Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Journal of the American College of Cardiology. 53:2028-2035. 2009
- Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. Internal and emergency medicine. 4:123-128. 2009
- Homocysteine-Lowering Therapy and Stroke Risk, Severity, and Disability. Stroke. 40:1365-1372. 2009
- Lipid lowering for primary prevention. The Lancet. 373:1152-1155. 2009
- Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study. AIDS Research and Therapy. 6:11-11. 2009
- Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). Vascular Medicine. 13:245-253. 2008
- Relationship between brachial artery flow-mediated dilatation, hyperemic shear stress, and the metabolic syndrome. Vascular Medicine. 13:263-270. 2008
- Hemodynamic Performance of Stentless Versus Stented Valves: A Systematic Review and Meta-Analysis. Journal of Cardiac Surgery. 23:556-564. 2008
- The effect of large unilamellar vesicles on vascular function in patients with coronary atherosclerosis. Atherosclerosis. 200:424-431. 2008
- Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. The Lancet. 372:1174-1183. 2008
- Usefulness of N-Terminal Pro–Brain Natriuretic Peptide and Brain Natriuretic Peptide to Predict Cardiovascular Outcomes in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction. American Journal of Cardiology. 102:733-737. 2008
- Reply. Nephrology Dialysis Transplantation. 23:2429-2430. 2008
- Effects of Intensive Glucose Lowering in Type 2 Diabetes. New England Journal of Medicine. 358:2545-2559. 2008
- Homocysteine-Lowering B Vitamin Therapy in Cardiovascular Prevention—Wrong Again?. Journal of the American Medical Association (JAMA). 299:2086-2086. 2008
- Effects of Ramipril and Rosiglitazone on Cardiovascular and Renal Outcomes in People With Impaired Glucose Tolerance or Impaired Fasting Glucose. Diabetes Care. 31:1007-1014. 2008
- Resting heart rate: A modifiable prognostic indicator of cardiovascular risk and outcomes?. Canadian Journal of Cardiology. 24:3A-15A. 2008
- Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 358:1547-1559. 2008
- BNP and NT‐proBNP predict echocardiographic severity of diastolic dysfunction. European Journal of Heart Failure. 10:252-259. 2008
- Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX). Atherosclerosis. 197:420-427. 2008
- Prevalence and predictors of subclinical atherosclerosis among asymptomatic “low risk” individuals in a multiethnic population. Atherosclerosis. 197:435-442. 2008
- Cardiac Function Stratification Based on Echocardiographic or Clinical Markers of Left Ventricular Filling Pressures Predicts Death and Hospitalization Better Than Stratification by Ventricular Systolic Function Alone. Echocardiography. 25:169-181. 2008
- Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. Nephrology Dialysis Transplantation. 23:645-653. 2008
- Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. Journal of the American Society of Echocardiography. 21:93-111. 2008
- Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis. American Journal of Clinical Nutrition. 87:168-174. 2008
- Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). American Heart Journal. 155:26.e1-26.e13. 2008
- The BEAUTIFUL Study: Randomized Trial of Ivabradine in Patients with Stable Coronary Artery Disease and Left Ventricular Systolic Dysfunction – Baseline Characteristics of the Study Population. Cardiology. 110:271-282. 2008
- Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?. Current Opinion in Hematology. 6:600-606. 2007
- Venous thromboembolism in association with features of the metabolic syndrome. QJM - Monthly Journal of the Association of Physicians. 100:679-684. 2007
- Randomized Clinical Trial of Homocysteine Level–Lowering Therapy and Fractures. JAMA Internal Medicine. 167:2136-2136. 2007
- Coronary artery disease - Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. American Heart Journal. 154:448-453. 2007
- Impact of ramipril on the incidence of atrial fibrillation: Results of the Heart Outcomes Prevention Evaluation study. American Heart Journal. 154:448-453. 2007
- [Wrong focus in the debate on burnout].. Lakartidningen. 104:2446. 2007
- Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima-medial thickness in male firefighters. Journal of Human Hypertension. 21:588-590. 2007
- Automated oscillometric blood pressure versus auscultatory blood pressure as a predictor of carotid intima–medial thickness in male firefighters. Journal of Human Hypertension. 21:588-590. 2007
- Reply. Journal of the American College of Cardiology. 50:79-80. 2007
- Homocysteine-Lowering Therapy and Risk for Venous Thromboembolism. ACP journal club. 146:761-761. 2007
- Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. European Heart Journal. 28:1382-1388. 2007
- Diastolic Dysfunction in Heart Failure With Preserved Systolic Function: Need for Objective Evidence. Journal of the American College of Cardiology. 49:687-694. 2007
- Giant Left Atrial Myxoma and Associated Mitral Valve Pathology. Journal of Cardiothoracic and Vascular Anesthesia. 21:103-105. 2007
- Apical ballooning syndrome, emotional stress and women: reply. European Heart Journal. 27:2908-2908. 2006
- Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine. 355:1551-1562. 2006
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. The Lancet. 368:1096-1105. 2006
- Impact of Ramipril on the Circadian Periodicity of Acute Myocardial Infarction. American Journal of Cardiology. 98:758-760. 2006
- Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 114:201-208. 2006
- Homocysteine, B vitamins, and cardiovascular disease - Reply. New England Journal of Medicine. 355:209-210. 2006
- Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review. European Heart Journal. 27:1523-1529. 2006
- Drug Therapies in the Secondary Prevention of Cardiovascular Diseases:Successes, Shortcomings and Future Directions. Current Vascular Pharmacology. 4:253-268. 2006
- Angiotensin-II receptor blockers and coronary artery disease: 'presumed innocents': reply. European Heart Journal. 27:1507-1508. 2006
- The effect of iron status on vascular health. Vascular Medicine. 11:85-91. 2006
- Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease. New England Journal of Medicine. 354:1567-1577. 2006
- Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. New England Journal of Medicine. 354:1464-1476. 2006
- Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: The Heart Outcomes Prevention Evaluation (HOPE)-2 trial. Canadian Journal of Cardiology. 22:47-53. 2006
- Intensity of Lipid Lowering With Statins and Brachial Artery Vascular Endothelium Reactivity After Acute Coronary Syndromes (from the BRAVER Trial). American Journal of Cardiology. 96:1207-1213. 2005
- Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' CollaborationThe opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. European Heart Journal. 26:2351-2353. 2005
- The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers. Atherosclerosis. 182:361-365. 2005
- The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 48:1749-1755. 2005
- Long-Term Effects of Ramipril on Cardiovascular Events and on Diabetes. Circulation. 112:1339-1346. 2005
- Left Atrial Appendage Occlusion Study (LAAOS): Results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. American Heart Journal. 150:288-293. 2005
- Vitamin E Supplementation, Cardiovascular Events, and Cancer—Reply. Journal of the American Medical Association (JAMA). 294:425-425. 2005
- The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. European Heart Journal. 26:1369-1378. 2005
- Relationship Between Carotid Artery Intima-Media Thickness and Brachial Artery Flow-Mediated Dilation in Middle-Aged Healthy Men. Journal of the American College of Cardiology. 45:1980-1986. 2005
- Surrogates of surrogates: the story of hypertension and 24 h blood pressure monitoring.. Canadian Journal of Cardiology. 21:639-642. 2005
- Effects of Long-term Vitamin E Supplementation on Cardiovascular Events and Cancer. Journal of the American Medical Association (JAMA). 293:1338-1338. 2005
- Effects of long-term supplementation on and cancer vitamin E cardiovascular events - A randomized controlled trial. Journal of the American Medical Association (JAMA). 293:1338-1347. 2005
- Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE Study. Clinical Nephrology. 63:181-187. 2005
- Should patients with stable coronary artery disease be treated with ACE inhibitor therapy?. Nature Reviews Cardiology. 2:124-125. 2005
- Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. European Journal of Preventive Cardiology (EJPC). 12:75-81. 2005
- Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease. American Journal of Cardiology. 95:249-253. 2005
- The HOPE (Heart Outcomes Prevention Evaluation) Study and its Consequences. Scandinavian Journal of Clinical and Laboratory Investigation. 65:143-156. 2005
- The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes. Diabetes Care. 27:2767-2767. 2004
- Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis. 176:361-370. 2004
- Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. Atherosclerosis. 176:361-370. 2004
- Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals. European Heart Journal. 25:1754-1760. 2004
- Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial. Diabetologia. 47:1519-1527. 2004
- C-Reactive Protein as a Screening Test for Cardiovascular Risk in a Multiethnic Population. Arteriosclerosis, Thrombosis and Vascular Biology. 24:1509-1515. 2004
- The clinical relevance of pharmacological blood pressure lowering mechanisms.. Canadian Journal of Cardiology. 20 Suppl B:83B-88B. 2004
- Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction. Journal of the American College of Cardiology. 43:2200-2206. 2004
- Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: Results of the HOPE Study. Kidney International. 65:1375-1380. 2004
- Prevalence of mitral valve prolapse in ethnic groups.. Canadian Journal of Cardiology. 20:511-515. 2004
- Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients. European Journal of Preventive Cardiology (EJPC). 10:420-428. 2003
- Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity.. Canadian Journal of Cardiology. 19:1387-1391. 2003
- Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: Results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases. 42:936-942. 2003
- Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. American Journal of Kidney Diseases. 42:936-942. 2003
- Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfusion Medicine Reviews. 17:272-286. 2003
- Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfusion Medicine Reviews. 17:272-286. 2003
- Relationship of Metabolic Syndrome and Fibrinolytic Dysfunction to Cardiovascular Disease. Circulation. 108:420-425. 2003
- Cardiovascular risk in patients with mild renal insufficiency. Kidney International, Supplement. 63:S192-S196. 2003
- Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 107:1284-1290. 2003
- Development of Renal Disease in People at High Cardiovascular Risk. Journal of the American Society of Nephrology. 14:641-647. 2003
- Multiple Infections and Subsequent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation. 107:251-257. 2003
- Left Atrial Appendage Occlusion Study (LAAOS): A randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. American Heart Journal. 145:174-178. 2003
- Mechanisms of cardiovascular risk reduction with ramipril: insights from HOPE and HOPE substudies. European Heart Journal, Supplement. 5:A43-A48. 2003
- The Relationship Between Dysglycemia and Atherosclerosis in South Asian, Chinese, and European Individuals in Canada. Diabetes Care. 26:144-149. 2003
- The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study.. Canadian Journal of Cardiology. 19:61-66. 2003
- Secondary prevention of ischaemic cardiac events.. Clinical Evidence. 129-168. 2002
- Effects of Vitamin E on Cardiovascular and Microvascular Outcomes in High-Risk Patients With Diabetes. Diabetes Care. 25:1919-1927. 2002
- Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis. Current Atherosclerosis Reports. 4:363-372. 2002
- Effect of long-term therapy with ramipril in high-risk women. Journal of the American College of Cardiology. 40:693-702. 2002
- Ramipril and cardiovascular risk reduction - Response. Circulation. 105:A194-A195. 2002
- Secondary prevention of ischaemic cardiac events.. Clinical Evidence. 124-160. 2002
- A pill for every ill - Response. Circulation. 105:E82-E82. 2002
- The T-786→C Mutation in Endothelial Nitric Oxide Synthase Is Associated With Hypertension. Hypertension. 39:919-922. 2002
- Use of ramipril in preventing stroke: double blind randomised trial. The BMJ. 324:699-699. 2002
- Effect of ramipril and vitamin E on atherosclerosis - Response. Circulation. 105:E5-E6. 2002
- Cardiovascular Risk in Patients with Early Renal Insufficiency. American Journal of Cardiovascular Drugs. 2:157-162. 2002
- Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.. Cardiovascular Drugs and Therapy. 16:149-160. 2002
- Do antioxidant vitamins protect against atherosclerosis? The proof is still lacking**Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.. Journal of the American College of Cardiology. 38:1795-1798. 2001
- Epidemiology of ischemic heart disease in women.. Canadian Journal of Cardiology. 17 Suppl D:14D-23D. 2001
- The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. American Journal of Cardiology. 88:1-20. 2001
- Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril. Circulation. 104:1615-1621. 2001
- Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). The Lancet. 358:1147-1153. 2001
- The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. Pharmacoepidemiology and Drug Safety. 10:497-508. 2001
- Effects of Ramipril on Coronary Events in High-Risk Persons. Circulation. 104:522-526. 2001
- Use of carotid ultrasound to stratify risk.. Canadian Journal of Cardiology. 17 Suppl A:22A-25A. 2001
- Effects of Ramipril and Vitamin E on Atherosclerosis. Circulation. 103:919-925. 2001
- Antiatherosclerotic Effects of ACE Inhibitors. American Journal of Cardiovascular Drugs. 1:315-320. 2001
- Dose response of ACE inhibitors: implications of the SECURE trial. Trials. 2:155-159. 2001
- Modifying the natural history of atherosclerosis: the SECURE trial.. International Journal of Clinical Practice, Supplement. 13-18. 2001
- Vitamin E supplementation in coronary artery disease and atherosclerosis. Surgeon. 30:90-93. 2001
- Homocysteine: to screen and treat or to wait and see?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 163:37-38. 2000
- Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). The Lancet. 356:279-284. 2000
- Regular review: Drug treatment in heart failure. The BMJ. 320:1188-1192. 2000
- Homocyst(e)ine and Cardiovascular Disease. ACP journal club. 132:676-676. 2000
- Homocyst(e)ine and Cardiovascular Disease. ACP journal club. 132:676-676. 2000
- Review: high levels of homocysteine are associated with an increased risk for cardiovascular disease. BMJ Evidence-Based Medicine. 5:63-63. 2000
- Differences in risk factors, atherosclerosis and cardiovascular disease between ethnic groups in Canada: the study of health assessment and risk in ethnic groups (SHARE).. Indian Heart Journal. 52:S35-S43. 2000
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. The Lancet. 355:253-259. 2000
- Echocardiographically guided pericardiocentesis - the gold standard for the management of pericardial effusion and cardiac tamponade.. Canadian Journal of Cardiology. 15:1251-1255. 1999
- Clinical Evidence: Emerging approaches in preventing cardiovascular disease.. Western Journal of Medicine. 171:247-252. 1999
- Emerging approaches in preventing cardiovascular disease. Western Journal of Medicine. 171:247-252. 1999
- Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence. ACP journal club. 131:363-363. 1999
- Role of antioxidant vitamins in prevention of cardiovascular diseases. The BMJ. 319:577-577. 1999
- Role of antioxidant vitamins in prevention of cardiovascular diseases - Meta-analysis seems to exclude benefit of vitamin C supplementation - Reply. The BMJ. 319:577-577. 1999
- Carotid artery intima-media thickness--a new noninvasive gold standard for assessing the anatomic extent of atherosclerosis and cardiovascular risk?. Clinical and Investigative Medicine. 22:158-160. 1999
- Emerging approaches in preventing cardiovascular disease. The BMJ. 318:1337-1341. 1999
- Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension. 21:835-845. 1999
- Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials. European Heart Journal. 19:1742-1742. 1998
- The Study of Health Assessment and Risk in Ethnic groups (SHARE): rationale and design. The SHARE Investigators.. Canadian Journal of Cardiology. 14:1349-1357. 1998
- The study of health assessment and risk in ethnic groups (SHARE): Rationale and design. Canadian Journal of Cardiology. 14:1349-1357. 1998
- Anti-ischaemic effects of ACE inhibitors: review of current clinical evidence and ongoing clinical trials.. European Heart Journal. 19 Suppl J:J36-J44. 1998
- Emerging approaches in the prevention of atherosclerotic cardiovascular diseases.. International Journal of Clinical Practice, Supplement. 94:7-19. 1998
- Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data.. Canadian Journal of Cardiology. 13:957-965. 1997
- Aggressive as opposed to moderate low-density lipoprotein cholesterol lowering strategies reduced the progression of atherosclerosis in grafts and reduced further revascularization. Evidence-based Cardiovascular Medicine. 1:49-49. 1997
- Study Design and Baseline Characteristics of the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E: SECURE**This study was supported by Research Grant Ul-12363 from the Medicine Research Council of Canada, Ottawa; and by Hoechst Marion Roussel, Laval, Canada, Inc.. American Journal of Cardiology. 78:914-919. 1996
- The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data (vol 123, pg 860, 1995). Annals of Internal Medicine. 124:934-934. 1996
- Acquired left ventricular to right atrial communication and complete heart block following nonpenetrating cardiac trauma.. Canadian Journal of Cardiology. 12:349-352. 1996
- The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.. Canadian Journal of Cardiology. 12:127-137. 1996
- Myocardial vacuolization, a marker of ischemic injury, in surveillance cardiac biopsies posttransplant: Correlations with morphologic vascular disease and endothelial dysfunction. Cardiovascular Pathology. 5:29-37. 1996
- The Antioxidant Vitamins and Cardiovascular Disease: A Critical Review of Epidemiologic and Clinical Trial Data. ACP journal club. 123:860-860. 1995
- Effects of ACE Inhibitors on Mortality When Started in the Early Phase of Myocardial Infarction: Evidence from the Larger Randomized Controlled Trials. European Journal of Preventive Cardiology (EJPC). 2:423-428. 1995
- Collaborative cardiovascular clinical trials in Canada. The Canadian Cardiovascular Collaboration.. Canadian Journal of Cardiology. 11:649-657. 1995
- Abnormalities in intramyocardial arteries detected in cardiac transplant biopsy specimens and lack of correlation with abnormal intracoronary ultrasound or endothelial dysfunction in large epicardial coronary arteries. Journal of the American College of Cardiology. 26:110-119. 1995
- Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.. Circulation. 90:2056-2069. 1994
- Effects of oxygen free radicals and scavengers on the cardiac extracellular collagen matrix during ischemia-reperfusion.. Canadian Journal of Cardiology. 10:203-213. 1994
- Primary and secondary prevention of myocardial infarction and strokes. Journal of Hypertension. 11:S61???S74-S61???S74. 1993
- INVITRO HIGH-RESOLUTION INTRAVASCULAR IMAGING IN MUSCULAR AND ELASTIC ARTERIES. Journal of the American College of Cardiology. 20:153-160. 1992
- In vitro high resolution intravascular imaging in muscular and elastic arteries. Journal of the American College of Cardiology. 20:153-160. 1992
- Reciprocal electrocardiographic changes in acute myocardial infarction. American Journal of Cardiology. 56:23-26. 1985